DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.

IF 1.9 4区医学 Q3 ONCOLOGY Cancer Biomarkers Pub Date : 2023-01-01 DOI:10.3233/CBM-230139

Yapeng Lu, Panpan Chang, Jiangpei Bian, Li Zhu

{"title":"DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.","authors":"Yapeng Lu, Panpan Chang, Jiangpei Bian, Li Zhu","doi":"10.3233/CBM-230139","DOIUrl":null,"url":null,"abstract":"Background: Dynein axonemal light intermediate chain 1 (DNALI1) is a component of axonemal dyneins and its role in cancer progression is not known.Objective: The influence of DNALI1 expression on the prognosis of low-grade gliomas (LGG) and the possible mechanisms of DNALI1 in promoting the progression of LGG was investigated by applying multiple bioinformatics analyses using datasets from TCGA, GTEx, CPTAC, and CGGA.Methods: The expression of DNALI1 in different tumor tissues including LGG was investigated. GO functional annotation, KEGG pathway analysis, and GSEA enrichment analysis were performed. The correlation between DNALI1 and prognosis, tumor microenvironment (TME) and immune checkpoints in LGG were assessed.Results: DNALI1 is mainly expressed in malignant cells in the TME of LGG and positively correlated with the development of LGG. DNALI1 expression is negatively correlated with isocitrate dehydrogenase (IDH) mutations and 1p/19q co-deletion. High DNALI1 expression is associated with poor prognosis in LGG. DNALI1 may promote LGG progression through multiple immune-related pathways. The expression of DNALI1 is positively correlated with the infiltration of certain types of immune cells and the expression of some immune checkpoints.Conclusions: DNALI1 is a potential prognostic marker for LGG, and high expression of DNALI1 may play an important role in maintaining the immunosuppressive microenvironment of LGG.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":" ","pages":"393-407"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/CBM-230139","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dynein axonemal light intermediate chain 1 (DNALI1) is a component of axonemal dyneins and its role in cancer progression is not known.

Objective: The influence of DNALI1 expression on the prognosis of low-grade gliomas (LGG) and the possible mechanisms of DNALI1 in promoting the progression of LGG was investigated by applying multiple bioinformatics analyses using datasets from TCGA, GTEx, CPTAC, and CGGA.

Methods: The expression of DNALI1 in different tumor tissues including LGG was investigated. GO functional annotation, KEGG pathway analysis, and GSEA enrichment analysis were performed. The correlation between DNALI1 and prognosis, tumor microenvironment (TME) and immune checkpoints in LGG were assessed.

Results: DNALI1 is mainly expressed in malignant cells in the TME of LGG and positively correlated with the development of LGG. DNALI1 expression is negatively correlated with isocitrate dehydrogenase (IDH) mutations and 1p/19q co-deletion. High DNALI1 expression is associated with poor prognosis in LGG. DNALI1 may promote LGG progression through multiple immune-related pathways. The expression of DNALI1 is positively correlated with the infiltration of certain types of immune cells and the expression of some immune checkpoints.

Conclusions: DNALI1 is a potential prognostic marker for LGG, and high expression of DNALI1 may play an important role in maintaining the immunosuppressive microenvironment of LGG.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

DNALI1是一种预后相关的生物标志物，与低级别胶质瘤的免疫浸润相关。

背景:动力蛋白轴突轻中间链1 (DNALI1)是轴突动力蛋白的一个组成部分，其在癌症进展中的作用尚不清楚。目的:利用TCGA、GTEx、CPTAC和CGGA的数据集，采用多种生物信息学分析方法，探讨DNALI1表达对低级别胶质瘤(LGG)预后的影响及DNALI1促进LGG进展的可能机制。方法:研究DNALI1在包括LGG在内的不同肿瘤组织中的表达。进行GO功能注释、KEGG通路分析和GSEA富集分析。评估DNALI1与LGG预后、肿瘤微环境(tumor microenvironment, TME)及免疫检查点的相关性。结果:DNALI1主要表达于LGG TME的恶性细胞中，与LGG的发生发展呈正相关。DNALI1的表达与异柠檬酸脱氢酶(IDH)突变和1p/19q共缺失负相关。DNALI1高表达与LGG预后不良相关。DNALI1可能通过多种免疫相关途径促进LGG进展。DNALI1的表达与某些类型免疫细胞的浸润和某些免疫检查点的表达呈正相关。结论:DNALI1是LGG的潜在预后标志物，DNALI1的高表达可能在维持LGG免疫抑制微环境中发挥重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.